Nicox attends the American Academy of Optometry 2013 annual meeting in Seattle

Nicox attends the American Academy of Optometry 2013 annual meeting in Seattle
...................................

October 18, 2013.

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX) is attending the 2013 annual meeting of the American Academy of Optometry 2013, taking place from October 23 to 26, 2013 in Seattle, Washington, United States. Nicox can be found at booth number 1004.
Nicox's US operational team, including Jerry St. Peter, Executive Vice President and General Manager of Nicox Inc, Jason Menzo, Director of Marketing, and Mark Puwal, National Director of Sales of Nicox Inc, will present AdenoPlus^®, a rapid point-of-care diagnostic test that aids in the differential diagnosis of acute conjunctivitis. AdenoPlus^® was launched by Nicox in the US in October 2012.

...................................

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new international player in the ophthalmic market by building a diversified portfolio of innovative therapies and diagnostic tools. With a heritage of scientific, business development and commercial expertise, the Nicox team is focused on developing and marketing novel pharmaceuticals and diagnostic devices that can help people to enhance their sight. In the United States, Nicox markets AdenoPlus^®, a test for the differential diagnosis of acute conjunctivitis in-licensed from RPS^®.

The Company's pipeline includes latanoprostene bunod, a novel drug-candidate based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, developed in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donating compounds are under development in non-ophthalmic indications, notably through partners, including Merck (known as MSD outside the United States and Canada).

Nicox S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps). For more information please visit www.nicox.com.

...................................

This communication may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés Financiers (AMF) on March 22, 2013 and available on Nicox's website (www.nicox.com) and on the AMF's website (www.amf-france.org).

...................................

Contacts

Nicox S.A.
Drakkar 2 | Bât D | 2405 route des Dolines | CS 10313 | Sophia Antipolis | 06560 Valbonne | France
T: +33 (0)4 97 24 53 00   |   F: +33 (0)4 97 24 53 99

www.nicox.com